BWL
NBIX icon

Bogart Wealth LLC’s Neurocrine Biosciences NBIX Stock Holding History

Bogart Wealth LLC’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.36K Buy
14
+9
+180% +$1.33K ﹤0.01% 1414
2026
Q1 		$659 Buy
5
+1
+25% +$133 ﹤0.01% 1526
2025
Q4 		$567 Sell
4
-4
-50% -$579 ﹤0.01% 1429
2025
Q3 		$1.12K Buy
8
+4
+100% +$542 ﹤0.01% 1258
2025
Q2 		$503 Buy
+4
New +$459 ﹤0.01% 1352

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bogart Wealth LLC's NBIX Position: Q2 2026 in Review

Bogart Wealth LLC increased its Neurocrine Biosciences (NBIX) stake by 180% in Q2 2026, buying an estimated $1.33K and bringing the position to 14 shares worth $2.36K. The position accounts for ﹤0.01% of the portfolio, ranked #1414.

Bogart Wealth LLC first reported a position in NBIX in Q2 2025 and has held it in 5 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Bogart Wealth LLC held 14 shares of Neurocrine Biosciences worth $2.36K as of Q2 2026.
  • Bogart Wealth LLC bought 9 Neurocrine Biosciences shares in Q2 2026, an estimated $1.33K.
  • Neurocrine Biosciences made up ﹤0.01% of Bogart Wealth LLC's portfolio in Q2 2026, its #1414 holding.
  • Bogart Wealth LLC first reported a position in Neurocrine Biosciences in Q2 2025 and has held it in 5 quarters since.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Bogart Wealth LLC's 13F filing for Q2 2026, filed 24 Jul 2026.